lanthanum has been researched along with Chronic Disease in 30 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.33) | 18.2507 |
| 2000's | 19 (63.33) | 29.6817 |
| 2010's | 10 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Iwamuro, M; Okada, H; Urata, H | 1 |
| Craig, JC; Elder, GJ; Natale, P; Palmer, SC; Ruospo, M; Strippoli, GF; Vecchio, M | 1 |
| Hutchison, AJ; Laville, M | 1 |
| Anger, M; Fishbane, S; Martin, KJ; Mehrotra, R; Sprague, SM; Zeig, S | 1 |
| Gulyaev, SM; Kozhevnikova, NM; Ubasheev, IO | 1 |
| Valdivieso, JM | 1 |
| Fernandez Giraldez, E; Sánchez González, MC; Valdivielso Revilla, JM | 1 |
| Spasovski, G | 1 |
| Abboud, H; Dauphin, M; Finn, W; Qiu, P; Sprague, SM; Zhang, P | 1 |
| Ben-Dov, IZ; Naveh-Many, T; Nechama, M; Silver, J | 1 |
| Koiwa, F; Sato, Y | 1 |
| Joki, N | 1 |
| Shigematsu, T; Tatsuta, K | 1 |
| Kazama, JJ | 1 |
| Taniguchi, M | 1 |
| Kadowaki, D; Maruyama, T | 1 |
| Ketteler, M | 1 |
| Fitchett, D; Jamal, SA; Lok, CE; Mendelssohn, DC; Tsuyuki, RT | 1 |
| Orita, H; Shigematsu, T; Tanaka, Y; Yamanaka, S; Yoshimoto, W | 1 |
| Yokoyama, K | 1 |
| Negi, S; Shigematsu, T | 1 |
| Campbell, SB; Hawley, CM; Isbel, NM; Johnson, DW; Mudge, DW; Petrie, JJ; van Eps, CL | 1 |
| Akizawa, T; Mizobuchi, M; Nakazawa, A | 1 |
| Flanigan, M; Haynes, WG; Kalil, RS; Stanford, W | 1 |
| Hamano, T | 1 |
| Hanba, Y; Masumoto, A; Moribata, M; Shigemathu, T | 1 |
| Boyle, JP; Pearson, HA; Peers, C; Plant, LD; Skinner, RA; Smith, IF | 1 |
| Brooks, T; Candiani, C; Hudson, JQ; Joy, MS; Kshirsagar, A | 1 |
| Brancaccio, D; Cozzolino, M; Fallabrino, G; Galassi, A; Gallieni, M; Pasho, S | 1 |
| Hawkins, CP; Landon, DN; McDonald, WI; Munro, PM | 1 |
20 review(s) available for lanthanum and Chronic Disease
| Article | Year |
|---|---|
Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).
Topics: Adult; Aged; Calcium; Calcium Compounds; Cause of Death; Chelating Agents; Chronic Disease; Chronic Kidney Disease-Mineral and Bone Disorder; Disease Progression; Fibroblast Growth Factor-23; Humans; Hypercalcemia; Iron Compounds; Lanthanum; Middle Aged; Parathyroid Hormone; Phosphorus; Polyamines; Randomized Controlled Trials as Topic; Renal Dialysis; Sevelamer | 2018 |
[Experimental advances in mineral metabolism].
Topics: Animals; Calcinosis; Calcium; Cardiovascular Diseases; Chelating Agents; Chelation Therapy; Chronic Disease; Drug Evaluation, Preclinical; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperparathyroidism, Secondary; Hyperphosphatemia; Intestinal Absorption; Kidney; Kidney Diseases; Lanthanum; Phosphorus; Sodium-Phosphate Cotransporter Proteins | 2008 |
[Control of phosphorus and treatment with vitamin D in chronic kidney disease prior to the start of dialysis].
Topics: Calcifediol; Calcinosis; Calcitriol; Cardiovascular Diseases; Chronic Disease; Chronic Kidney Disease-Mineral and Bone Disorder; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperphosphatemia; Kidney Diseases; Lanthanum; Phosphorus; Polyamines; Prevalence; Renal Dialysis; Sevelamer; Vitamin D; Vitamin D Deficiency | 2008 |
New strategies in treatment of mineral and bone disorders and associated cardiovascular disease in patients with chronic kidney disease.
Topics: Calcinosis; Cardiovascular Diseases; Chronic Disease; Humans; Kidney Diseases; Lanthanum; Minerals; Parathyroid Hormone; Phosphates; Polyamines; Sevelamer | 2008 |
[Management of phosphate in chronic kidney disease--Chemistry and history of phosphate binder].
Topics: Administration, Oral; Aluminum Compounds; Calcium Carbonate; Chronic Disease; Humans; Hypercalcemia; Hyperphosphatemia; Kidney Diseases; Lanthanum; Phosphates; Polyamines; Renal Dialysis; Sevelamer; Vitamin D | 2009 |
[Pharmacodynamic and pharmacokinetic profile of lanthanum carbonate].
Topics: Chronic Disease; Humans; Hyperphosphatemia; Kidney Diseases; Lanthanum; Renal Dialysis; Tissue Distribution | 2009 |
[Management of phosphate in chronic kidney disease--Clinical trials of lanthanum carbonate].
Topics: Chronic Disease; Humans; Hyperphosphatemia; Kidney Diseases; Lanthanum; Randomized Controlled Trials as Topic | 2009 |
[Is lanthanum carbonate a safe drug?].
Topics: Administration, Oral; Chronic Disease; Drug-Related Side Effects and Adverse Reactions; Humans; Hyperphosphatemia; Kidney Diseases; Lanthanum | 2009 |
[Use of phosphate binder in predialysis patients].
Topics: Calcium Carbonate; Chronic Disease; Dialysis; Drug Approval; Humans; Hyperphosphatemia; Japan; Kidney Diseases; Lanthanum; Polyamines; Prognosis; Sevelamer | 2009 |
[To facilitate the compliance of phosphate binder for the control of hyperphosphatemia in chronic kidney disease patients].
Topics: Chronic Disease; Drug Administration Schedule; Hyperphosphatemia; Kidney Diseases; Lanthanum; Patient Compliance; Patient Education as Topic; Polyamines; Sevelamer | 2009 |
The control of hyperphosphatemia in chronic kidney disease: which phosphate binder?
Topics: Chelating Agents; Chronic Disease; Fibroblast Growth Factor-23; Humans; Hyperphosphatemia; Kidney Diseases; Lanthanum; Polyamines; Renal Dialysis; Sevelamer | 2009 |
The effects of calcium-based versus non-calcium-based phosphate binders on mortality among patients with chronic kidney disease: a meta-analysis.
Topics: Acetates; Calcium Carbonate; Calcium Compounds; Cause of Death; Chelating Agents; Chronic Disease; Humans; Kidney Diseases; Lanthanum; Polyamines; Sevelamer | 2009 |
[Secondary osteoporosis UPDATE. Therapy for bone-mineral disease in CKD-5D patients].
Topics: Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcium; Cardiovascular Diseases; Chelating Agents; Chronic Disease; Contraindications; Dialysis; Diphosphonates; Fractures, Spontaneous; Kidney Diseases; Lanthanum; Minerals; Polyamines; Sevelamer | 2010 |
[CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Paradigm shift in CKD-MBD guideline].
Topics: Bone Density; Bone Diseases, Metabolic; Chronic Disease; Cinacalcet; Dialysis; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Lanthanum; Naphthalenes; Practice Guidelines as Topic | 2010 |
[CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Lanthanum carbonate and new phosphate binders in patients with chronic kidney disease].
Topics: Cardiovascular Diseases; Chronic Disease; Drug Design; Hyperphosphatemia; Kidney Diseases; Lanthanum; Renal Dialysis; Risk | 2010 |
[Bone and calcium update; diagnosis and therapy of metabolic bone disease update. Advances in treatment of CKD-MBD].
Topics: Bone Diseases, Metabolic; Chronic Disease; Cinacalcet; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Klotho Proteins; Lanthanum; Membrane Proteins; Naphthalenes; Vascular Calcification; Vitamin D | 2011 |
[Kidney and bone update : the 5-year history and future of CKD-MBD. Pharmacoeconomics in the field of CKD-MBD].
Topics: Bone Diseases, Metabolic; Carbamates; Chelating Agents; Chronic Disease; Cinacalcet; Cost-Benefit Analysis; Humans; Kidney Diseases; Lanthanum; Minerals; Naphthalenes; Parathyroidectomy; Polyamines; Sevelamer; Vitamin D | 2012 |
[Kidney and bone update : the 5-year history and future of CKD-MBD. Progress of phosphate binders].
Topics: Aluminum Hydroxide; Calcium Carbonate; Chelating Agents; Cholestyramine Resin; Chronic Disease; Diet, Protein-Restricted; Drug Design; Humans; Hyperphosphatemia; Ion Exchange Resins; Kidney Diseases; Lanthanum; Phosphorus, Dietary; Polyamines; Sevelamer | 2012 |
Lanthanum carbonate.
Topics: Animals; Chronic Disease; Clinical Trials as Topic; Humans; Kidney Diseases; Lanthanum; Phosphorus; Treatment Outcome | 2006 |
Preventive measures and new pharmacological approaches of calcium and phosphate disorders.
Topics: Calcium; Chronic Disease; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Lanthanum; Naphthalenes; Phosphates; Polyamines; Renal Dialysis; Sevelamer; Vitamin D | 2008 |
4 trial(s) available for lanthanum and Chronic Disease
| Article | Year |
|---|---|
Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Calcium; Canada; Chronic Disease; Dose-Response Relationship, Drug; Europe; Female; Humans; Hyperphosphatemia; Israel; Kidney Diseases; Lanthanum; Male; Middle Aged; Outcome Assessment, Health Care; Parathyroid Hormone; Phosphates; Prospective Studies; Renal Dialysis; Treatment Outcome | 2008 |
Higher strength lanthanum carbonate provides serum phosphorus control with a low tablet burden and is preferred by patients and physicians: a multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Chronic Disease; Drug Administration Schedule; Female; Humans; Hyperphosphatemia; Kidney Diseases; Lanthanum; Male; Middle Aged; Patient Satisfaction; Phosphorus; Renal Dialysis; Tablets; Time Factors; Treatment Outcome; United States | 2008 |
Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Chronic Disease; Double-Blind Method; Female; Humans; Hyperphosphatemia; Kidney Diseases; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Renal Dialysis; Severity of Illness Index; Time Factors; Treatment Outcome | 2009 |
Dissociation between progression of coronary artery calcification and endothelial function in hemodialysis patients: a prospective pilot study.
Topics: Aged; Biomarkers; Brachial Artery; Calcium; Chelating Agents; Chronic Disease; Coronary Artery Disease; Disease Progression; Endothelium, Vascular; Humans; Iowa; Kidney Diseases; Lanthanum; Middle Aged; Phosphorus; Pilot Projects; Polyamines; Prospective Studies; Renal Dialysis; Sevelamer; Time Factors; Treatment Outcome; Vascular Calcification; Vasodilation | 2012 |
6 other study(ies) available for lanthanum and Chronic Disease
| Article | Year |
|---|---|
Relationship between gastric lanthanum deposition and Helicobacter pylori-associated chronic gastritis: is it rare or common?
Topics: Chronic Disease; Gastric Mucosa; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lanthanum | 2017 |
Morphological assessment of the cerebroprotective action of lanthanum acetate in chronic cerebral ischemia in rats.
Topics: Acetates; Animals; Brain Ischemia; Calcium Channel Blockers; Chronic Disease; Cinnarizine; Female; Lanthanum; Male; Neurons; Neuroprotective Agents; Rats; Rats, Wistar | 2008 |
Regulation of PTH mRNA stability by the calcimimetic R568 and the phosphorus binder lanthanum carbonate in CKD.
Topics: 3' Untranslated Regions; Adenine; Aniline Compounds; Animals; Calcium; Chronic Disease; Disease Models, Animal; Half-Life; Hyperparathyroidism, Secondary; Kidney Diseases; Lanthanum; Male; Parathyroid Glands; Parathyroid Hormone; Phenethylamines; Phosphates; Phosphorus, Dietary; Propylamines; Rats; RNA Stability; RNA-Binding Proteins; RNA, Messenger; Time Factors; Trans-Activators | 2009 |
Do aluminium-based phosphate binders continue to have a role in contemporary nephrology practice?
Topics: Aluminum; Bone Diseases; Chelating Agents; Chronic Disease; Humans; Hyperphosphatemia; Kidney Diseases; Lanthanum; Polyamines; Renal Dialysis; Sevelamer | 2011 |
Chronic hypoxia potentiates capacitative Ca2+ entry in type-I cortical astrocytes.
Topics: Amyloid beta-Peptides; Animals; Animals, Newborn; Astrocytes; Bradykinin; Calcium; Calcium Channel Blockers; Cell Hypoxia; Cells, Cultured; Cerebral Cortex; Chelating Agents; Chronic Disease; Enzyme Inhibitors; Hypoxia, Brain; Lanthanum; Membrane Potentials; Mitochondria; Peptide Fragments; Rats; Time | 2003 |
Metabolically dependent blood-brain barrier breakdown in chronic relapsing experimental allergic encephalomyelitis.
Topics: 2,4-Dinitrophenol; Animals; Blood-Brain Barrier; Chronic Disease; Dinitrophenols; Encephalomyelitis, Autoimmune, Experimental; Gadolinium; Guinea Pigs; Lanthanum; Magnetic Resonance Imaging; Pentetic Acid; Perfusion; Permeability; Recurrence | 1992 |